Hot Startup Theranos Has Struggled With Its Blood-Test Technology

This copy is for your personal, non-commercial use only. Distribution and use of this material are governed by our Subscriber Agreement and by copyright law. For non-personal use or to order multiple copies, please contact Dow Jones Reprints at 1-800-843-0008 or visit www.djreprints.com.

https://www.wsj.com/articles/theranos-has-struggled-with-blood-tests-1444881901

On Theranos Inc.’s website, company founder Elizabeth Holmes holds up a tiny vial to show how the startup’s “ breakthrough advancements have made it possible to quickly process the full range of laboratory tests from a few drops of blood.”

The company offers more than 240 tests, ranging from cholesterol to cancer. It claims its technology can work with just a finger prick. Investors have poured more than $400 million into Theranos, valuing it at $9 billion and her majority stake at more than half that. The 31-year-old Ms. Holmes’s bold talk and black turtlenecks draw comparisons to Apple Inc. cofounder Steve Jobs.

But Theranos has struggled behind the scenes to turn the excitement over its technology into reality. At the end of 2014, the lab instrument developed as the linchpin of its strategy handled just a small fraction of the tests then sold to consumers, according to four former employees.

YouTube to Pay $24.5 Million to Settle Lawsuit Brought by Trump

The TV Boss Who Kicked Kimmel Off His Stations and Started a Firestorm

Senators Want Answers From Big Tech on H-1B Workers, Layoffs

U.S. Tech Giants Pledge Over $40 Billion in U.K. Investments Ahead of Trump Visit